Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies: response to study by Hayama et al.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L. Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(12):1520–41.

    Article  CAS  PubMed  Google Scholar 

  2. 2.

    Weycker D, Bensink M, Lonshteyn A, Doroff R, Chandler D. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. Curr Med Res Opin. 2017;33(12):2107–13.

    Article  PubMed  Google Scholar 

  3. 3.

    Hayama T, Sakurai K, Miura K, Washinosu S, Tsuboi S, Uchiike A, Yoshida Y, Takei M. Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies. Int J Clin Pharm. 2018;40(5):997–1000.

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353(10):988–98.

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Loibl S, Mueller V, von Minckwitz G, Conrad B, Koehne CH, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V. Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer. 2011;19(11):1789–95.

    Article  PubMed  Google Scholar 

Download references

Funding

Funding for the preparation of this letter was provided by Amgen Inc. to Policy Analysis Inc. (PAI).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Derek Weycker.

Ethics declarations

Conflicts of interest

Mark Bensink Ph.D., M.Sc., M.Ed., Prasad Gawade, Ph.D., and Rajesh Belani, M.D. are employed by Amgen Inc. Derek Weycker, Ph.D. is employed by PAI. David Henry, M.D. is employed by Penn Medicine.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Henry, D.H., Weycker, D., Bensink, M. et al. Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies: response to study by Hayama et al.. Int J Clin Pharm 41, 619–620 (2019). https://doi.org/10.1007/s11096-018-0752-3

Download citation